Zura Bio Limited (NASDAQ:ZURA) Given Consensus Recommendation of “Buy” by Brokerages

Zura Bio Limited (NASDAQ:ZURA) has been given an average recommendation of “Buy” by the seven brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $15.80.

Several equities research analysts recently weighed in on ZURA shares. Leerink Partnrs upgraded Zura Bio to a “strong-buy” rating in a research note on Monday, November 4th. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research report on Wednesday, December 11th. Leerink Partners began coverage on shares of Zura Bio in a report on Monday, November 4th. They issued an “outperform” rating and a $15.00 target price for the company. HC Wainwright reiterated a “neutral” rating and set a $5.00 price target on shares of Zura Bio in a research note on Tuesday. Finally, Piper Sandler reissued an “overweight” rating and issued a $26.00 price target on shares of Zura Bio in a research report on Thursday, September 19th.

Insider Activity at Zura Bio

In related news, Director Parvinder Thiara sold 1,001,633 shares of the business’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $2.73, for a total value of $2,734,458.09. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 22.10% of the stock is owned by insiders.

Institutional Trading of Zura Bio

Hedge funds have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. purchased a new stake in shares of Zura Bio during the second quarter worth approximately $8,446,000. Armistice Capital LLC increased its stake in Zura Bio by 53.2% in the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock valued at $8,834,000 after buying an additional 876,000 shares during the period. The Manufacturers Life Insurance Company purchased a new position in Zura Bio during the 3rd quarter worth $71,000. Braidwell LP acquired a new stake in shares of Zura Bio in the 3rd quarter worth $10,040,000. Finally, Great Point Partners LLC boosted its holdings in shares of Zura Bio by 68.3% in the second quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock valued at $16,248,000 after acquiring an additional 1,884,501 shares in the last quarter. 61.14% of the stock is owned by institutional investors and hedge funds.

Zura Bio Stock Performance

ZURA stock opened at $2.32 on Wednesday. Zura Bio has a fifty-two week low of $2.00 and a fifty-two week high of $6.35. The company’s 50 day moving average price is $3.52 and its 200 day moving average price is $3.67.

Zura Bio (NASDAQ:ZURA) last posted its earnings results on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.12). Equities analysts anticipate that Zura Bio will post -0.65 earnings per share for the current fiscal year.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.